Health-care companies fell as traders rotated out of a sector likely to face more regulation. President-elect Donald Trump is set to give Robert F. Kennedy Jr., his pick as Health and Human Services ...
Apple stock rises after falling Thursday by the most since August, Alphabet stock is up after the Supreme Court upholds a ban ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often ...
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
By Berkeley Lovelace Jr. The Biden administration on Friday released the next round of prescription drugs selected ...
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...
The U.S. government targets Novo Nordisk's drugs, including Ozempic and Wegovy, for Medicare price negotiations in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback